search

Active clinical trials for "Lymphoma, Large B-Cell, Diffuse"

Results 1031-1040 of 1161

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years...

Diffuse Large B Cell LymphomaAge Over 80 Years

About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.

Unknown status16 enrollment criteria

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB...

Non-GCB/ABC Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma5 more

Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma

Unknown status41 enrollment criteria

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2...

Diffuse Large B Cell Lymphoma

This study is a one-arm, open, multicenter phase 1b/2 clinical trial of YY-20394 combined with GEMOX second-line or above in patients with relapsed and/or refractory diffuse large B-cell lymphoma. YY-20394 combined with GEMOX was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of GEMOX was treated according to clinical standards.

Unknown status4 enrollment criteria

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20)...

Diffuse Large B Cell Lymphoma

This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.

Unknown status57 enrollment criteria

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory...

Diffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma2 more

This is an open-label, multicenter, dose-escalation phase 1 study to determine the safety and efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma.

Unknown status59 enrollment criteria

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma....

Diffuse Large B-Cell LymphomaSintilimab1 more

The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.

Unknown status22 enrollment criteria

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL...

Diffuse Large B Cell Lymphoma

This is a single-arm, open-label phase 2 study of iR2 in the treatment of unfit and elderly patients with untreated diffuse large B-cell lymphoma。

Unknown status14 enrollment criteria

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Diffuse Large B Cell LymphomaFollicular Lymphoma5 more

Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)

Unknown status17 enrollment criteria

A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With...

Diffuse Large B-Cell Lymphoma

This is a randomised, double-blind, positive drug parallel controlled equivalence clinical trial initiated at about 30 sites in China. In the trial, it is planned to enroll 414 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.

Unknown status36 enrollment criteria

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive...

CD19-positiveDiffuse Large B-cell Lymphoma1 more

To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive diffuse large B-cell lymphoma and follicular lymphoma. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.

Unknown status28 enrollment criteria
1...103104105...117

Need Help? Contact our team!


We'll reach out to this number within 24 hrs